sequencing in patient CHRO628-II:4. The single-nucleotide variant (SNV) list from whole-exome sequencing was filtered for the homozygosity interval on chromosome 1, resulting in the identification of a homozygous missense variant, c.970C>T (p.Arg324Cys), in ATF6 that segregated in the family ( Fig. 1a and Supplementary  Fig. 1 ). The ATF6 variant altered a highly conserved arginine residue in the bZIP domain necessary for dimerization ( Supplementary  Fig. 2 ), which is not only conserved in the ATF protein family but also in the entire activator protein (AP)-1 protein family 19 (data not shown). (b) cDNA analysis of the putative splice-site mutations. RNA was extracted from PaxGene-isolated blood samples for patients as well as from a healthy control sample, reverse transcribed, PCR amplified and Sanger sequenced. In all cases, the splice-site mutations were shown to lead to aberrantly spliced products (MT), but small amounts of correctly spliced cDNA (WT) are also visible. Lanes (from left to right): size standard patient cDNA, healthy control cDNA and no-template negative control. Left, c.82+5G>T in CHRO282; sequencing of the aberrant band showed intron retention of the first 88 bp of intron 1. Middle, c.1187+5G>C in CHRO709; sequencing of the aberrant band showed exon skipping of exon 9, thereby deleting 92 bp from the ORF. Right, c.1533+1G>C in CHRO593; sequencing of the aberrant bands showed that the larger band is due to intron retention of the first 83 bp of intron 12 whereas the smaller band results from exon skipping of exon 12.
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A r t i c l e s
Further whole-exome sequencing and candidate gene screening of ATF6 in 301 patients with ACHM identified 15 additional patients from 9 independent families segregating disease-causing variants in ATF6, totaling 18 patients from 10 independent families (Fig. 1a, Table 1 , Supplementary Fig. 1 and Supplementary Table 1) . Three affected siblings from a UK family (CHRO91; also known as GC13874) were also homozygous for the original missense mutation c.970C>T (encoding a p.Arg324Cys substitution), and haplotype reconstruction from SNP chip data indicated that all carriers of this mutation share a 0.7-Mb common homozygous haplotype flanked by SNPs rs4072409 and rs16840028, suggestive of a founder mutation in the Irish and UK population or identity by descent. Five French-Canadian patients from three independent families (MOGL5414, CHRO593 and MOGL411-MOGL467) carried a homozygous variant (c.1533+1G>C) affecting the consensus splice donor sequence of exon 12 in ATF6. This finding is also suggestive of a founder mutation in the French-Canadian population, but SNP chip data were only available for the affected individuals from family MOGL411-MOGL467, who shared a 5.4-Mb homozygous region encompassing ATF6. Sanger sequencing of all coding exons and flanking intronic sequences and comparison of the sequences for all patients carrying the homozygous c.1533+1G>C allele showed that all had the same homozygous SNP genotype, at least for the ATF6 gene, as documented on the basis of homozygosity of two rare SNPs, rs371893818 and rs374093774. Two German siblings were compound heterozygous with a 1-bp duplication on each allele of ATF6 (c.797dupC; p.Asn267* and c.1110dupA; p.Val371Serfs*3). The remaining patients harbored other, private homozygous diseasecausing variants, including another homozygous missense mutation, c.1699T>A (p.Tyr567Asn), in an Iranian achromat mapping to a C-terminal amino acid sequence motif that is conserved in ATF6A and ATF6B ( Supplementary Figs. 1 and 2) ; a homozygous 1-bp deletion, c.353delC, in a Turkish achromat resulting in a frameshift after Pro118 (p.Pro118Leufs*31); and two further homozygous variants affecting canonical splice donor sites: c.82+5G>T in a patient from South Tyrol (Italy) and c.1187+5G>C in two Asian-Indian achromat sisters. In total, we identified eight different disease-causing variants ( Table 1, Supplementary Fig. 1 and Supplementary Table 1) . The putative disease-causing variants were not observed in our in-house databases, dbSNP or the Exome Variant Server (EVS). The c.970C>T allele was observed to be heterozygous in 3 of 120,904 genotypes called by the ExAC browser. The missense mutations were predicted to be disease causing by various prediction software packages (for example, MutationTaster, SIFT and PolyPhen).
We directly assessed the effect of variants putatively affecting consensus splice-site sequences by extracting RNA from PaxGeneisolated blood samples for the patients carrying the putative disease-causing variant, synthesizing the corresponding cDNA, and evaluating the products on agarose gels and by Sanger sequencing. All three variants affecting the consensus donor splice site were shown to result in missplicing, frameshift and premature termination codons (PTCs) (Fig. 1b and Table 1 ). Consequently, the mutant proteins are expected to be severely truncated, or-more likely-the transcripts undergo nonsense-mediated decay. Yet, evaluation on agarose gels provided evidence that small amounts of correctly spliced ATF6 mRNA are expressed, at least in blood lymphocytes (Fig. 1b) . The disease-causing variant c.82+5G>T led to exonification (intron retention) of 88 bp of intron 1, which thereby resulted in a frameshift and subsequent PTC (p.Asp28Glyfs*36) (Supplementary Table 1 ). The disease-causing variant c.1187+5G>C in turn caused exon skipping of exon 9 (92 bp), also resulting in a frameshift and PTC (p.Asn366Hisfs*12) (Supplementary Table 1 ). The diseasecausing variant c.1533+1G>C showed two aberrant spliced bands: the larger band corresponded to exonification (intron retention) of 83 bp of intron 12, leading to a PTC (p.Gly512Leufs*39), and the smaller band corresponded to exon skipping of exon 12, which is 100 bp in size, also resulting in a PTC (p.Leu479Valfs*11) (Supplementary Table 1) .
Clinical phenotype
The clinical data for the 18 patients are summarized in Supplementary Table 1. All patients had a clinical diagnosis of complete (n = 16) or incomplete (n = 2) ACHM based on psychophysical and/or electrophysiological findings. Nystagmus and photophobia were present in all from birth or early infancy. All patients had very poor or absent color vision and markedly reduced visual acuity. There was no evidence of progression over time except in one patient (CHRO649-II:1). Best corrected visual acuity was severely reduced (range of 20/63 to 20/200), and refractive error ranged from −9.5 to +6.0 diopters Funduscopic examinations identified small, well-defined, oval-shaped RPE defects with pathological wall and foveal reflexes in each case. Defects were seen in the FAF images as parafoveal hyperfluorescent areas in the younger cases and hypofluorescent spots surrounded by a ring with increased autofluorescence in older cases. SD-OCT images showed loss of cone inner and outer segments with interruption of the ciliary layer and disruption of the RPE layer in the foveal area. All patients presented with almost missing foveal pits, which may be characteristic of the retinal disorder caused by ATF6 mutations. Pictures were not available for the patients from families CHRO593 and CHRO282. Color photography, FAF and SD-OCT images for a healthy control individual, together with labeling of the retinal layers in the SD-OCT image, are provided at the bottom right. ELM, external limiting membrane; GCL, ganglion cell layer; ILM, internal limiting membrane; INL, inner nuclear layer; IPL, inner plexiform layer; IS/OS, photoreceptor inner and outer segments; NFL, nerve fiber layer; ONL, outer nuclear layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium. Dark adaptation was evaluated in two patients (CHRO628-II:2 and CHRO628-II:4), who showed rod-mediated function lacking the rod-cone break and cone branch, with dark-adaptation thresholds being within normal limits. Scotopic full-field electroretinography (ERG) responses were within normal limits, consistent with normal rod function, whereas photopic full-field ERG responses were either severely reduced or not detectable, in keeping with absent or markedly reduced cone system function (Fig. 2a) .
Findings from anterior segment examination were normal. Fundus examination and color fundus photography showed healthy optic discs, intact retinal vasculature and normal peripheral retina. The macula showed a range of changes from relatively normal areas to welldemarcated sites of atrophy that did not appear to be related to age ( Fig. 2b and Supplementary Table 1) . Fundus autofluorescence (FAF) imaging showed variable changes, including parafoveal areas or rings of increased autofluorescence in younger cases and areas of reduced autofluorescence corresponding to atrophy seen clinically surrounded by a ring of increased signal in some subjects (Fig. 2b) . Spectral domain-optical coherence tomography (SD-OCT) scans showed foveal hypoplasia with a missing foveal pit in all patients ( Fig. 2b and Supplementary Table 1 ). In keeping with previous detailed reports of retinal integrity in ACHM, SD-OCT scans showed variable disruption of the inner segment ellipsoid (ISe) layer (photoreceptor layer) at the fovea 1,2 ( Fig. 2b and Supplementary Table 1) .
Although SD-OCT allows retinal lamination to be identified, adaptive optics scanning light ophthalmoscopy (AOSLO) allows direct visualization of cone photoreceptors. Therefore, AOSLO was performed to assess cone photoreceptor mosaic integrity in siblings of the affected individual from family CHRO628 (Fig. 3) . Instead of a complete and continuous cone photoreceptor mosaic, we observed dark areas devoid of wave-guiding cones and highly reflective regions. Comparison of the AOSLO image with the SD-OCT scan showed that the dark areas observed in AOSLO correlated with absence of an ISe layer in SD-OCT, and hyper-reflective regions correlated with dome-shaped hyporeflective deposits in SD-OCT (Fig. 3a) . For b and c, a P value of <0.05 was considered significant (*P < 0.05, **P < 0.01, ***P < 0.001, Student's two-tailed t test).
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A r t i c l e s AOSLO montage images showed the obvious ring sharp and dark area with missing or invisible cone cells, which correlated with the absence of an inner segment-outer segment junction in SD-OCT (Fig. 3b) . The average cone density (18,142.25/mm 2 ) of a 0.5-mm eccentricity area was considerably lower than for the normal group (32,554 ± 2,884/mm 2 ). The average cone density of a 1.0-mm eccentricity area (14,997.5/mm 2 ) was also lower than normal (19,802 ± 1,460/mm 2 ). In contrast, the average cone density of a 1.5-mm eccentricity area (14,302.75/mm 2 ) was higher than in the normal group (11,249 ± 1,967/mm 2 ). According to these results, only cones in the macular area and part of the paramacular area were affected. Hearing loss was observed in four patients. Patient CHRO649-II:1, homozygous for the mutation encoding p.Tyr567Asn, had bilateral sensorineural hearing loss diagnosed at 1 year of age, hypothyroidism since childhood and celiac disease. However, her elder sister (CHRO649-II:2), who also had bilateral early-onset sensorineural hearing loss, had a normal eye examination and is heterozygous for the mutation in ATF6 encoding p.Tyr567Asn. All three siblings of family CHRO91 (GC13874), homozygous for the mutation encoding p.Arg324Cys, presented with sensorineural hearing loss with age of onset between 25 and 35 years. All other patients with ACHM were otherwise healthy, with the youngest patient being 8 years old and the oldest 94 years old. The possibility cannot be excluded that the finding of ACHM and sensorineural hearing loss in these individuals may be related to the ATF6 mutations, yet the situation in family CHRO649 suggests that this co-occurrence is a coincidence.
Functional studies on patient fibroblasts
Human ATF6 disease-causing variant causes loss of ATF6 transcriptional activity. To determine how human ATF6 disease-causing variants affected ATF6A function, we collected fibroblasts from individuals in family CHRO628 homo-or heterozygously carrying the ATF6 variant encoding p.Arg324Cys. We exposed fibroblasts from the heterozygous mother (CHRO628-I:2) and the three homozygous, affected children (CHRO628-II:2, CHRO628-II:4 and CHRO628-II:6) in medium to tunicamycin, an inhibitor of N-linked glycosylation that causes protein misfolding in the ER and potently activates ATF6A. As HSPA5 (encoding GRP98; also known as BiP) is one of the most highly induced transcriptional targets of ATF6A 15, 16 , we tested the Topography of ATF6A and the location of the disease-causing variants identified in patients with ACHM. The diagram depicts the transactivation domain, including the VN8 domain, the bZIP domain and an ERTM domain 39 . In the C-terminal region, a domain of unknown function that is conserved between ATF6A and ATF6B is also indicated. VN8, eight-residue domain homologous to herpes simplex viral protein VP16 necessary for optimal transcriptional activity and degradation 31 ; bZIP, basic leucine-zipper domain; ERTM, endoplasmic reticulum transmembrane domain.
effect of the variant on transcriptional activation. All of the patientderived fibroblasts homozygous for the ATF6 mutation encoding p.Arg324Cys showed significantly reduced HSPA5 mRNA and GRP78 (BiP) protein induction after tunicamycin exposure in comparison to fibroblasts derived from the heterozygous carrier mother (Fig. 4a,b) . Analysis of additional ATF6A downstream transcriptional targets, including HERPUD1, SEL1L and EDEM1, also showed significantly reduced mRNA induction for these genes after tunicamycin exposure in all patient-derived fibroblasts homozygous for the ATF6 mutation encoding p.Arg324Cys (Fig. 4b) . These findings suggested that the fibroblasts with homozygous ATF6 mutation were defective in ATF6 transcriptional activity. To rule out the possibility that transcriptional differences arose from genetic variation between the different fibroblast cell lines, we used a system in which wild-type ATF6A or Arg324Cys ATF6A was fused to the dihydrofolate reductase (DHFR) protein to create fusion ATF6A transcription factors whose activities could be specifically regulated by the addition of trimethoprim. This strategy has previously been shown to enable potent activation of ATF6A transcription independently of ER stress and activation of other UPR signaling pathways 20 . We transfected HEK293 cells with construct for wild-type or Arg324Cys ATF6 fusion proteins and confirmed expression of the human DHFR-ATF6A fusion proteins via immunoblotting (Fig. 4c) . After addition of trimethoprim, HSPA5 mRNA and GRP78 (BiP) protein levels were significantly induced in cells expressing DHFR fused to wild-type ATF6A (Fig. 4c) . By contrast, HSPA5 mRNA and GRP78 (BiP) protein levels were not induced in cells expressing DHFR fused to the Arg324Cys ATF6A mutant (Fig. 4c) . Taken together, our studies demonstrate that the ATF6 mutation encoding p.Arg324Cys compromises ATF6A transcriptional activity. Young Atf6 −/− mouse retinas appear normal. We investigated whether retinal protein expression was altered in 3-month-old Atf6 −/− homozygous-knockout, Atf6 +/− heterozygous and Atf6 +/+ wild-type mouse littermates. In retinas collected from these mice under ambient conditions, there was no obvious difference in the steady-state expression levels of the cone-specific M-opsin, S-opsin and glycogen phosphorylase proteins (Supplementary Fig. 3b) . Similarly, there were no differences in expression of rod-specific proteins, including rhodopsin (Rho) and rod α-transducin (Gαt1; encoded by Gnat1) (Supplementary Fig. 3c ). Lastly, we observed no significant upregulation of ER stress-induced proteins, including PDI, calreticulin and BiP, among Atf6 −/− , Atf6 +/− and Atf6 +/+ littermates ( Supplementary  Fig. 3d ). Taken together, our findings indicate that cones are present and functional in 3-month-old Atf6 −/− mice, and that there are no significant differences in protein levels among Atf6 −/− , Atf6 +/− and Atf6 +/+ littermates.
Retinal alterations in aged Atf6 −/− mice. We performed functional studies based on ERG of Atf6 −/− mice and respective Atf6 +/+ controls at the ages of 3, 5 and 18 months. Full-field ERG measurements allowed the assessment of both dark-adapted (scotopic), rod-dominated responses and light-adapted (photopic), cone-driven responses 21 . ERG recordings of younger Atf6 −/− mice showed normal rod and cone activity, when compared to Atf6 +/+ control littermates (Fig. 5a, top) . However, functional analysis of 18-month-old Atf6 −/− mice and corresponding Atf6 +/+ controls showed that both rod and cone single-flash ERG responses were markedly reduced in Atf6 −/− mice (Fig. 5a, bottom) . In contrast to human ACHM, the functional deficits in mice show that the rod and cone systems are affected only at an older age.
We assessed retinal morphology in Atf6 −/− and corresponding control mice at 3, 5 and 18 months of age by in vivo confocal scanning-laser ophthalmoscopy (cSLO) and SD-OCT imaging. Fundus appearance, vasculature and retinal layering in mutant mice did not show any differences in comparison to controls at 3 and 5 months of age (Fig. 5b) . However, for mice at 18 months of age, we could observe retinal degeneration (Fig. 5b) . Fundus imaging showed spot-like disturbances, which could be correlated to hyperfluorescent spots detected in autofluorescence cSLO imaging mode (Fig. 5b) . Degeneration of photoreceptors results in the accumulation of autofluorescent material, which can be detected in cSLO imaging 22, 23 ; thus, spot-like enhanced autofluorescence clearly indicates ongoing retinal degeneration. As observed in patients, retinal vasculature also appeared unaffected in the mouse model (Fig. 5b, angiography) . Further in vivo analysis of retinal layering by SD-OCT imaging showed a disruption of the layers corresponding to the inner and outer segments (Fig. 5b) , which could also be observed in the human clinical phenotype; however, in mouse retinas, the retinal pigment epithelium (RPE) layer was also affected (Fig. 5b, SD- OCT magnification, arrowheads in the SD-OCT full scan).
All these findings suggest that there is a profound difference in the function and impact of Atf6a in mouse and human retinal development and maintenance. Foveas are only found in primates, birds and in one lizard species. Perhaps this explains why ATF6A does not have a role in mouse retinal development, as mice do not develop foveas.
To determine whether cones were lost in Atf6 −/− mice at 12 months of age, we analyzed retina flat-mounts from heterozygous Atf6 +/− and homozygous-knockout Atf6 −/− mice and labeled cones with peanut agglutinin (PNA) (Supplementary Fig. 3a) . We found no gross difference in the number of PNA-labeled cells between Atf6 −/− and Atf6 +/− littermates at 12 months of age.
Nuclear staining on retinal sections of the same 18-month-old knockout mice and wild-type controls previously assessed electrophysiologically and morphologically in vivo showed a median of 10 rows of photoreceptors in wild-type mice and 7-8 rows of nuclei in the outer nuclear layer in Atf6 −/− homozygous-knockout mice (Fig. 5c) . Such a reduction is suggestive of a potential mild degenerative process.
DISCUSSION
Mutations in ATF6 are a rare cause of ACHM. Extrapolating the numbers from of our patient cohort, we conclude that about 1% of European-ancestry individuals with ACHM carry mutations in this 
or incomplete ACHM. Although a clear genotype-phenotype correlation could not be observed, interestingly, all our ATF6-associated patients with ACHM had marked foveal hypoplasia, including persistent inner retinal layers at the fovea and a poorly formed or absent foveal pit. Foveal hypoplasia can also be present in ACHM caused by mutations in phototransductionassociated genes (up to 70-80% of cases, depending on the definition of foveal hypoplasia) [1] [2] [3] [4] [5] , but the absence of foveal development is rare. As we found this phenotype in all 18 patients from 10 independent families, we hypothesize that severe foveal hypoplasia with a poorly formed or absent foveal pit may be a hallmark of ATF6-related disease that distinguishes it from other forms of ACHM, where the pathogenesis relates to abnormalities of the cone phototransduction pathway. It is evident that ATF6 does not primarily affect cone phototransduction but has a key role in foveal development, alongside a generalized effect on cone function. This observation is further corroborated by the adaptive optics images of individual cones showing that only central foveal cones are missing, whereas peripheral cones may be present. This finding is consistent with a foveal developmental defect in individuals with ATF6-associated ACHM. The counts of cones outside of the central 1.5-mm area in both children examined are supranormal, but the cones are non-functional, as ERGs are extinguished. The presence of peripheral cones suggests that ATF6-associated ACHM may be amenable to gene therapy, as has also been shown in animal models for ACHM caused by mutations in GNAT2, , and clinical phase I and II safety studies are in preparation for the latter two.
ATF6 encodes a ubiquitously expressed 90-kDa ER stress-regulated transmembrane transcription factor, required for ER stress response and transcriptional induction from ER stress-response elements (ERSEs) in the promoter regions of genes encoding ER protein chaperones, ER-associated protein degradation and ER protein trafficking 14, 15, 24, 28 . Upon induction of ER stress, the cytosolic ~400-residue N-terminal portion of ATF6A (N-ATF6Ap50) is released as a result of regulated intramembraneous proteolysis 16, 29 . N-ATF6Ap50 possesses a transcriptional activation domain, a bZIP domain, a DNA-binding domain and nuclear localization signals (Fig. 6) . N-ATF6Ap50 then translocates to the nucleus, where it interacts with several other proteins to form an ERSE-binding complex that is responsible for the induction of ER stress genes (ERSGs), including the ER chaperone HSPA5 (encoding glucose-regulated protein, 78 kDa (GRP78); also known as BiP) 16, 29, 30 . N-ATF6Ap50 is rapidly degraded in a proteasome-mediated process 31 . Thus, similar to several other potent transcription factors that exert rapid, transient effects 32 , the degradation of ATF6A upon transcriptional engagement apparently serves as a mechanism to rapidly turn off ERSG induction 33 .
Another member of the ATF/CREB family of transcription factors highly homologous to ATF6A-ATF6B-is also an ER membrane protein that is cleaved during ER stress to generate an N-terminal fragment of ~400 residues 34 . N-ATF6A and N-ATF6B possess highly conserved bZIP domains and DNA-binding domains. This conservation allows N-ATF6A and N-ATF6B to bind to ERSEs as homo-or heterodimers 35 ; however, the functional relevance of the binding of N-ATF6B to ERSEs, either alone or as a heterodimer with N-ATF6A, is currently unknown. In addition, these proteins share an 18-residue motif of unknown function in the C terminus (Supplementary Fig. 2) . Whole-body deletion of either Atf6 or Atf6b in mouse does not result in markedly aberrant phenotypes in the absence of ER stress, but deletion of both genes results in an early embryonic lethal phenotype, indicating that these genes provide overlapping functions early in development 28, 36 . In the presence of ER stress, Atf6 −/− mice cannot activate adaptive UPR transcription, whereas Atf6b −/− mice can adapt to ER stress 28, [36] [37] [38] . Thus, ATF6A and not ATF6B is the major mechanism through which UPR gene expression is activated and promotes the survival of cells with ER stress. Functional and morphological analysis in vivo of the corresponding gene-deletion mouse model showed a phenotype affecting both the rod and cone photoreceptor systems at older ages (Fig. 5) .
The missense substitution p.Arg324Cys found in this study localizes to the basic region of the bZIP domain, affecting an arginine residue that is not only conserved among transcription factors of the ATF family but also in those of the AP-1 family (Fig. 6 and Supplementary  Fig. 2) . The impact on UPR in cells expressing this disease-causing variant was tested in fibroblasts from family CHRO628 (Fig. 4) . Fibroblasts homozygous for the ATF6 mutation encoding p.Arg324Cys showed substantially reduced HSPA5 mRNA and GRP78 (BiP) protein induction after tunicamycin exposure in comparison to the fibroblasts heterozygous for the mutation. The heterologous expression of ATF6A Arg324Cys fused to DHFR protein in HEK293 cells resulted in complete loss of HSPA5 mRNA and GRP78 (BiP) protein, whereas there was significant induction by wild-type ATF6A fused to DHFR in the control experiment. Both results indicate that the ATF6 disease-causing variant encoding p.Arg324Cys severely impairs ATF6 transcriptional activity.
The second missense substitution, p.Tyr567Asn, alters a tyrosine residue in the C-terminal part of ATF6A. This residue is completely conserved among all known ATF6 homologs down to zebrafish and is located and conserved in an 18-residue sequence motif of unknown function that is present in both ATF6A and ATF6B ( Fig. 6 and  Supplementary Fig. 2) .
The disease-causing variants affecting consensus splice-site sequences, as well as the 1-bp deletion c.353delC and the 1-bp duplications c.797dupC and c.1110dupA, were all shown to result in frameshift and PTC (Figs. 1b and 6 , and Table 1 ). Most likely, the corresponding aberrant transcripts will undergo nonsensemediated decay. If translated, all transcripts would lead to considerably truncated ATF6 polypeptides. However, cDNA analysis of the disease-causing splice-site variants also showed that, in the analyzed whole-blood samples derived from patients, small amounts of correctly spliced ATF6 transcripts could be amplified, suggesting that these patients may also produce small amounts of wild-type ATF6A polypeptide (Fig. 1b) .
Our study identified ATF6 as an additional gene implicated in ACHM and associated with foveal hypoplasia. It links ATF6 to human disease and highlights the finding that the ubiquitously expressed ATF6, known for its function in UPR, has an important role in the development and function of the fovea and cone photoreceptors. 
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ONLINE METHODS
Subjects and clinical examination. Study participants were recruited over 10 years from international collaborating centers specialized in inherited retinal diseases. Blood or DNA samples were sent to Tübingen, Germany, for genetic investigation. This and all our studies were performed according to the tenets of the Declaration of Helsinki, and all participants gave written consent, approved by the respective local research and ethical review boards.
Patients underwent comprehensive ophthalmological examination including, depending on the center, psychophysical testing (best-corrected visual acuity, color vision, visual field testing (n = 2) and dark adaptation (n = 2)), electrophysiological assessment (including full-field and multifocal ERG) and retinal imaging (including color fundus photography, FAF and SD-OCT). Color vision was assessed with various tests including Ishihara plates, Lanthony's Tritan album (LTA), American Optical Hand-Hardy-Rittler (AOHRR), the saturated Roth 28-Hue test, Farnsworth Munsell 100-Hue tests and the Nagel anomaloscope. Dark-adaptation thresholds, full-field ERG and multifocal ERG recordings were measured in accordance with ISCEV recommendations 40, 41 . AOSLO was performed in patient CHRO628-II:2 as described previously [42] [43] [44] [45] .
Molecular genetic analysis. DNA was isolated from peripheral blood according to standard procedures in the different centers and banked at the Institute for Ophthalmic Research (Tübingen, Germany) according to standard protocol.
Linkage analysis and homozygosity mapping. For one family (CHRO628), DNA for all family members was genotyped using Affymetrix GeneChip Human Mapping 250K NspI SNP arrays. Linkage analysis was performed by applying the easyLINKAGE software package 46 , using Allegro v1.2c and assuming autosomal recessive inheritance in the family (Fig. 1a) . Homozygosity mapping was performed by applying Homozygosity mapper software 47 .
Exome sequencing. Whole-exome sequencing of DNA from CHRO628-II:4 was performed by a commercial provider (CeGaT), applying the Agilent insolution SureSelect All Exon kit (Agilent Technologies) run on a SOLiD 4 system (Applied Biosystems). All reads were mapped to the human reference genome (GRCh37/hg19), applying the Bioscope and Lifescope packages (Applied Biosystems). SNV calling was implemented with a Frequentist algorithm on high-coverage positions or with a Bayesian algorithm. In addition, the Lifescope and Bioscope programs both supported indel calling. Diseasecausing variants will be submitted to ClinVar. Exome data can be provided upon request within a scientific cooperation.
Candidate gene screening by Sanger sequencing. All coding exons and flanking intronic and UTR sequences of ATF6 (RefSeq, NM_007348.3) were PCR amplified from genomic DNA (purified by treatment with ExoSAP-IT (GE Healthcare)) and sequenced with dye-termination chemistry (BigDye Terminator version 1.1, Applied Biosystems). For primer sequences and PCR conditions, see Supplementary Table 2 . Sequences were run on a capillary sequencer (ABI 3100, Applied Biosystems) and analyzed with Sequence Analysis software (version 5.1, Applied Biosystems) and sequence trace alignment software (SeqMan, DNASTAR). Segregation analysis was performed by Sanger sequencing.
Evaluation of variants in consensus splice-site sequences. Total RNA was extracted from PaxGene blood tubes (Qiagen) for patients CHRO282, CHRO593 and CHRO709 (GC4040) according to the manufacturer's recommendations and reverse transcribed to test for missplicing caused by the following variants in canonical splice-site sequences: c.82+5G>T, c.1187+5G>C and c.1533+1G>C. Exonic ATF6-specific primers located in exon 1 and exon 4, exon 8 and exon 10, and exon 11 and exon 13, respectively, were used for amplification of wild-type versus mutant cDNA. PCR fragments were electrophoretically separated on 2% agarose gels, visualized by ethidium bromide staining and evaluated. PCR products were then purified, Sanger sequenced and analyzed as described above.
